Dossier assessment

Guselkumab (plaque psoriasis in children and adolescents) – Benefit assessment according to §35a Social Code Book V

Status
Status: Commission completed
Project no.
A25-163
Last updated

Report documents

  1. Extract of dossier assessment

    Guselkumab (plaque psoriasis in children and adolescents) – Benefit assessment according to §35a Social Code Book V

    published on
    Document type
    PDF document, 271 kB, DE, not accessible
  2. Dossier assessment

    Guselkumab (plaque psoriasis in children and adolescents) – Benefit assessment according to §35a Social Code Book V

    published on
    Document type
    PDF document, 548 kB, DE, not accessible
    DOI-Link
    https://doi.org/10.60584/A25-163

Drug assessment at a glance

  1. Drug assessment at a glance

    Guselkumab (plaque psoriasis in children and adolescents) – Benefit assessment according to §35a Social Code Book V

    published on
    Document type
    PDF document, 205 kB, EN, not accessible

Dossier assessment

Indication:

Children and adolescents from the age of 6 years with moderate to severe plaque psoriasis for whom systemic therapy is an option

Result of dossier assessment:

Added benefit not proven

Project details

Project no.
A25-163
Commission
Commission awarded on 23.12.2025 by the Federal Joint Committee (GBA).
Report type
Dossier assessment
Status
Commission completed
Department/Division
Drug Assessment
Topic
Skin and hair
Note

After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.

DOI

https://doi.org/10.60584/A25-163

Connected Projects

  1. Dossier assessment

    Guselkumab (Crohn’s disease) – Benefit assessment according to §35a Social Code Book V

    Project no.
    A25-75
    Last updated

    Status: Commission completed

  2. Dossier assessment

    Guselkumab (ulcerative colitis) – Benefit assessment according to §35a Social Code Book V

    Project no.
    A25-74
    Last updated

    Status: Commission completed

  3. Dossier assessment

    Guselkumab (psoriatic arthritis) - Benefit assessment according to §35a Social Code Book V

    Project no.
    A20-112
    Last updated

    Status: Commission completed

  4. Dossier assessment

    Guselkumab (plaque psoriasis) - Benefit assessment according to §35a Social Code Book V

    Project no.
    A17-60
    Last updated

    Status: Commission completed

Contact

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form